Archives: Speakers

Dina Kofler has been with Medinol since 2013. As VP Clinical Affairs, she leads the clinical department and manages all clinical trial activities including the pivotal trials that constituted the clinical basis for the EluNIR DES’ approval in the United States, Europe and Israel. Before joining Medinol, Dina worked at MediWound Ltd. and prior to that she worked for 14 years at Teva Pharmaceutical Industries Ltd and held various clinical-trial management positions. She holds B.Sc. in Biology from the Tel Aviv University and an MBA from the Herriot-Watt University’s Edinburgh Business School.

Experienced Global Category Manager with a demonstrated history of working in the pharmaceuticals industry. Skilled in U.S. Food and Drug Administration (FDA) regulations in the Clinical Trials area, Oncology, CNS and Pain , CRO Management and supply chain for Clinical Trials. Strong operations professional with a Master in Health Administration focused in Health/Health Care Administration/Management from Tel Aviv University.

Matt is responsible for defining and leading the product strategy for ERT’s digital patient product line, with a focus on direct to patient enablement in both post approval research and patient support. Matt has spent the last 12 years leading teams and innovating products in both the clinical research and commercial healthcare settings to reduce patient burden of participation and to support patients in their healthcare journey.  Most recently, Matt was Global Head of Patient Engagement for ICON’s Commercialization & Outcomes division and, prior to that, Head of Direct to Patient Research (Virtual Trials) at IQVIA.

Jorge Garcia Perez is VP Sales and Marketing at Lactips. Economist and head of Research chair, he has significant experience in complex sales. Having worked as a consultant for the European Union working with technology companies in Spain, Finland, Portugal, Italy, France, he joined Lactips in 2018.

Experienced Chief Operations Officer and Government Affairs professional with a demonstrated history of working in the healthcare industry, security field and public sector. Skilled in Operations Management, Government, Entrepreneurship, Legal Management and Strategy. American Israeli strong legal professional with a Bachelor of Laws (LL.B.) IDC Herzliya.

Isaac Israel has served as Kitov’s Chief Executive Officer and a member of the board since 2012. Prior to joining Kitov, Mr. Israel founded BeeContact (formerly TASE: BCNT) and served as CEO from 2001 to 2007. Mr. Israel has served as owner and founding CEO of Uneri Capital, a capital market consulting firm specializing in healthcare, since 2008. He serves on the board of various public and private healthcare corporations, including chairman of the board of NextGen Biomed, which is traded on the TASE.

Moshe has been the President and CEO of 3QBD since 2006. Moshe’s team are bringing a new Technology to the Bio-Diagnostic market, with some of their 1st applications include OBS and Gyn. Diagnosing the Vaginal Flora in less than 90 seconds. 3QBD detect: BV, Trichomoniasis, Candida Albican, Infections caused by pathogens. simultaneously by one test
We are looking for Distributors in Europe specially East Europe.

David has been the CEO of Dali Medical since 2003. Dali Medical develop Innovative Injectable Drug Delivery Devices – from product concept to regulatory approval and commercialization. Their R&D activities include Developing novel concepts for auto-injectors and Safe Auto-Needles for self-administration of injectable drugs and biologics, bringing these concepts from a general idea to a commercially available device through and Technology transfer to external contract manufacturers and subcontractors both in Israel and internationally